Philogen Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dario Neri

Amministratore delegato

€150.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	28.8yrs
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Dario Neri (61 yo)

28.8yrs

Mandato

€150,000

Compensazione

Prof. Dr. Dario Neri, PhD co-founded Philogen S.p.A in 1996 and serves as its CSO, President of The Scientific Advisory Board and Chief Executive Officer and Managing Director. Prof. Dr. Neri served as Sc...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Duccio Neri	Co-Founder & Executive Chairman	no data	€300.00k	Nessun dato
Dario Neri	Co-Founder	no data	€150.00k	Nessun dato
Giovanni Neri	Co-Founder	no data	€90.00k	Nessun dato
Roberto Ferraresi	Independent Director	5.5yrs	€32.00k	Nessun dato
Sergio Gianfranco Luigi Dompé	Director	no data	€30.00k	0.025% € 203.0k
Leopoldo Zambeletti	Director	no data	€30.00k	Nessun dato
Nathalie Francesca Dompé	Director	no data	€30.00k	Nessun dato
Guido Guidi	Member of Scientific Advisory Board & Director	5.5yrs	€32.00k	Nessun dato
Marta Bavasso	Lead Independent Director	no data	€30.00k	Nessun dato
Wolfgang Berdel	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Cornelia Winter	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Maria Calloni	Director	2.8yrs	€32.00k	Nessun dato

5.5yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 78Q sono considerati esperti (durata media dell'incarico 5.5 anni).

Philogen Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Director recently bought €179k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Recent updates

First half 2024 earnings released

Less than half of directors are independent

Director recently bought €179k worth of stock

Full year 2023 earnings released

Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma

Philogen S.p.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities

New major risk - Revenue and earnings growth

Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma

First half 2023 earnings released: EPS: €0.19 (vs €0.049 in 1H 2022)

Philogen S.p.A. (BIT:PHIL) commences an Equity Buyback Plan for 500,000 shares, representing 1.23% of its issued share capital, under the authorization approved on April 28, 2023.

Less than half of directors are independent

First half 2022 earnings released: EPS: €0 (vs €0.21 loss in 1H 2021)

Philogen S.p.A. Announces Enrolment of 214 Patients in the Nidlegy Phase III European Clinical Trial for the Treatment of Locally Advanced Melanoma

Less than half of directors are independent

Full year 2021 earnings released

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Director recently bought €4.7m worth of stock

Director recently bought €4.4m worth of stock

Philogen S.p.A. Announces R&D Program Update

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media